Metastatic Hormone Refractory Prostate Cancer Completed Phase 1 Trials for Docetaxel (DB01248)

Also known as: Metastatic hormone refractory Prostate cancer / Metastatic Prostate cancer / Prostate cancer metastatic / Metastatic Prostate Carcinoma / Carcinoma of the prostate metastatic / Prostatic cancer metastatic

DBCOND0036371 (Metastatic Hormone Refractory Prostate Cancer)Completed1 IdentifierTitlePurposeDrugs
NCT00415779ZANTE: Zometa and Taxotere in Hormone Refractory Prostate CancerTreatment